708 related articles for article (PubMed ID: 19169607)
1. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
[TBL] [Abstract][Full Text] [Related]
5. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
8. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
9. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].
Fattoruso SI; Rossi S; Vici P; Di Filippo F; Botti C; Di Lauro L; Foggi P; Saracca E; Ferranti FR; Visca P; Lopez M
Clin Ter; 2008; 159(6):443-7. PubMed ID: 19169606
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Spielmann M; Roché H; Delozier T; Canon JL; Romieu G; Bourgeois H; Extra JM; Serin D; Kerbrat P; Machiels JP; Lortholary A; Orfeuvre H; Campone M; Hardy-Bessard AC; Coudert B; Maerevoet M; Piot G; Kramar A; Martin AL; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(36):6129-34. PubMed ID: 19917839
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.
Costa RB; Kurra G; Greenberg L; Geyer CE
Ann Oncol; 2010 Nov; 21(11):2153-2160. PubMed ID: 20351072
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
14. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
15. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Yardley DA; Hart L; Waterhouse D; Whorf R; Drosick DR; Murphy P; Badarinath S; Daniel BR; Childs BH; Burris H
Breast Cancer Res Treat; 2013 Dec; 142(3):655-65. PubMed ID: 24253810
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
17. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
18. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.
Metcalfe S; Evans J; Priest G
N Z Med J; 2007 Jun; 120(1256):U2593. PubMed ID: 17589560
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]